PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25609059-4	2015	RESULTS: We confirm that both trabectedin and doxorubicin were able to strongly reduce EWS-FLI1 (both type I and type II) binding to two representative target genes (TGFbetaR2 and CD99), both in vitro and in xenografts.	Trabectedin	30-41	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	91-95	
25809543-1	2015	PURPOSE: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1.	Trabectedin	122-133	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	242-246	
25609059-5	2015	However, trabectedin, but not doxorubicin, was also able to increase the occupancy of EWS-FLI1 to IGF1R promoters, leading to IGF1R upregulation.	Trabectedin	9-20	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	90-94	
24277455-5	2014	Because WRN-deficient cells are known to be hypersensitive to camptothecins, we utilize trabectedin to block EWS-FLI1 activity, suppress WRN expression, and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38.	Trabectedin	88-99	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	113-117	
21403840-4	2011	We demonstrate that, among a panel of pediatric sarcomas, Ewing sarcoma family of tumors (ESFTs) cell lines bearing the EWS-FLI1 transcription factor are the most sensitive to treatment with ET-743 compared with osteosarcoma, rhabdomyosarcoma, and synovial sarcoma.	Trabectedin	191-197	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	124-128	
21403840-5	2011	We show that ET-743 reverses a gene signature of induced downstream targets of EWS-FLI1 in two different ESFT cell lines (P = .001).	Trabectedin	13-19	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	83-87	
21403840-6	2011	In addition, ET-743 directly suppresses the promoter activity of a known EWS-FLI1 downstream target NR0B1 luciferase reporter construct without changing the activity of a constitutively active control in ESFT cells.	Trabectedin	13-19	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	77-81	
21403840-7	2011	Furthermore, the effect is specific to EWS-FLI1, as forced expression of EWS-FLI1 in a cell type that normally lacks this fusion protein, HT1080 cells, induces the same NR0B1 promoter, but this activation is completely blocked by ET-743 treatment.	Trabectedin	230-236	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	43-47	
21403840-7	2011	Furthermore, the effect is specific to EWS-FLI1, as forced expression of EWS-FLI1 in a cell type that normally lacks this fusion protein, HT1080 cells, induces the same NR0B1 promoter, but this activation is completely blocked by ET-743 treatment.	Trabectedin	230-236	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	77-81